$46.56
1.06% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
GB00BYMT0J19
Symbol
LIVN

Livanova PLC Stock price

$46.56
-5.92 11.28% 1M
-8.27 15.08% 6M
-5.18 10.01% YTD
-5.64 10.80% 1Y
-40.72 46.65% 3Y
-28.84 38.25% 5Y
-8.89 16.03% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.50 1.06%
ISIN
GB00BYMT0J19
Symbol
LIVN
Sector

Key metrics

Market capitalization $2.53b
Enterprise Value $2.54b
P/E (TTM) P/E ratio 109.24
EV/FCF (TTM) EV/FCF 23.39
EV/Sales (TTM) EV/Sales 2.05
P/S ratio (TTM) P/S ratio 2.04
P/B ratio (TTM) P/B ratio 1.93
Revenue growth (TTM) Revenue growth 10.69%
Revenue (TTM) Revenue $1.24b
EBIT (operating result TTM) EBIT $137.27m
Free Cash Flow (TTM) Free Cash Flow $108.67m
Cash position $666.58m
EPS (TTM) EPS $0.43
P/E forward 83.14
P/S forward 2.02
EV/Sales forward 2.03
Short interest 5.65%
Show more

Is Livanova PLC a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Livanova PLC Stock Analysis

Unlock Scores for Free

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

8x Buy
89%
1x Hold
11%

Analyst Opinions

9 Analysts have issued a Livanova PLC forecast:

Buy
89%
Hold
11%

Financial data from Livanova PLC

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
1,238 1,238
11% 11%
100%
- Direct Costs 394 394
12% 12%
32%
844 844
10% 10%
68%
- Selling and Administrative Expenses 471 471
6% 6%
38%
- Research and Development Expense 181 181
2% 2%
15%
192 192
34% 34%
15%
- Depreciation and Amortization 54 54
9% 9%
4%
EBIT (Operating Income) EBIT 137 137
66% 66%
11%
Net Profit 24 24
720% 720%
2%

In millions USD.

Don't miss a Thing! We will send you all news about Livanova PLC directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Livanova PLC Stock News

Neutral
Business Wire
11 days ago
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC announced that Brain Stimulation published two pivotal articles chronicling the unipolar cohort data set for the RECOVER clinical study.
Neutral
Business Wire
24 days ago
LONDON--(BUSINESS WIRE)-- #cardiacsurgery--LivaNova PLC today announced its participation in the American Epilepsy Society (AES) 2024 Annual Meeting, taking place Dec. 6-10 in Los Angeles.
Neutral
Business Wire
about 2 months ago
LONDON--(BUSINESS WIRE)-- #advancedcirculatorysupport--LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.
More Livanova PLC News

Company Profile

LivaNova Plc is a global medical technology company, which engages in the development and delivery of important therapeutic solutions for the benefit of patients, healthcare professionals and healthcare systems. It operates through the following segments: Cardiovascular and Neuromodulation. The Cardiovascular segment develops, produces, and sells cardiopulmonary products, heart valves, and advanced circulatory support products. The Neuromodulation segment designs and markets NM-based medical devices for the treatment of epilepsy, depression, and obstructive sleep apnea. The company was founded on February 20, 2015 and is headquartered in London, the United Kingdom.

Head office United Kingdom
CEO Vladimir Makatsaria
Employees 2,900
Founded 1987
Website www.livanova.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today